Desvenlafaxine Succinate (Pristiq): Postmarketing Surveillance Study Among Filipino Patients

Pfizer

Status: Terminated

Conditions: Major Depressive Disorder; Vasomotor Symptoms

Treatments: Drug: desvenlafaxine succinate

Study type: Observational

Funder types: Industry

Identifiers

NCT01353963

B2061038

Details and patient eligibility

About

This is a non-interventional study to review safety data on administration of desvenlafaxine succinate among Filipino patients with MDD and VMS per usual clinical practice within the first three years post commercial distribution.

Full description

post marketing surveillance none

Enrollment: 13 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Patients diagnosed with major depressive disorder and vasomotor symptoms secondary to menopause prescribed with desvenlafaxine succinate

Exclusion criteria

Hypersensitivity to desvenlafaxine succinate

Trial design

13 participants in 1 patient group

1

Treatment:

Drug: desvenlafaxine succinate